Covid-19 roundup: RECOVERY trial halts recruitment for colchicine study after finding ‘no convincing evidence’; Italy blocks AstraZeneca vaccine shipment meant for Australia
It may be the end of the road for colchicine, an inexpensive oral anti-inflammatory drug commonly used to treat gout, as a potential Covid-19 treatment — at least in hospitalized patients.
The UK’s RECOVERY trial put out the word on Friday that it’s halting enrollment in its colchicine study after a data monitoring committee saw “no convincing evidence that further recruitment would provide conclusive proof of worthwhile mortality benefit either overall or in any pre-specified subgroup.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters